Ignite Creation Date:
2024-05-06 @ 4:05 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04863638
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-06-18
First Post:
2021-04-27
Brief Title:
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine Vero Cell Inactivated
Sponsor:
China National Biotec Group Company Limited
Organization:
China National Biotec Group Company Limited
Study Overview
Official Title:
A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine Vero Cell Inactivated in Population Aged 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
COVID-19
Brief Summary:
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine Vero Cell Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged 18-59 years old with 2-dose schedule And subjects in the same age are randomly assigned to different immunization schedule groups
Detailed Description:
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine Vero Cell Inactivated and in population aged 60 years old and 3-17 years old with different schedules D02142 D0 21111or D021171compared to that in population aged 18-59 years old with 2-dose schedule D021 And subjects in the same age are randomly assigned to different immunization schedule groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None